Hutchmed (NASDAQ:HCM) announced on April 9, 2026, that it will present a series of new preclinical and clinical datasets at the American Association for Cancer Research (AACR) Annual Meeting.
The presentations, scheduled for April 17-22 in San Diego, will focus on the company’s emerging antibody-targeted toxic compound (ATTC) platform and expanded applications for its approved therapies.
The highlight of the upcoming scientific session is the debut of preclinical data for HMPL-A580, a novel EGFR-targeted ATTC utilizing a PI3K/PIKK inhibitor payload.
According to the company, the compound demonstrated high potency with an IC50 ~1–10 nM, ranging from approximately 1 to 10 nM.
In mouse xenograft studies, HMPL-A580 showed dose-dependent antitumor activity at levels between 1 and 10 mg/kg.
The data also indicated favorable pharmacokinetic profiles in cynomolgus monkeys and high plasma stability across multiple species, suggesting a viable path toward clinical development.
Beyond its early-stage pipeline, the Hong Kong-based biotechnology firm will provide updates on its commercialized drug, surufatinib.
The company will share findings from investigator-initiated Phase Ib/II and exploratory Phase II studies.
These trials evaluate surufatinib in combination with other therapies for the treatment of small bowel, appendiceal, and pancreatic cancers, as the company seeks to broaden the clinical utility of the drug beyond its current indications for neuroendocrine tumors.